Merrion prepares Phase III study for Orazol in breast cancer treatment

[News]

After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.

More... (http://www.news-medical.net/news/20101116/Merrion-prepares-Phase-III-study-for-Orazol-in-breast-cancer-treatment.aspx)